Catalyst Pharmaceuticals, Inc.
US ˙ NASDAQCM ˙ US14888U1016 ˙ Medical Devices
DIESES SYMBOL IST NICHT MEHR AKTIV

SecurityCPRX / Catalyst Pharmaceuticals, Inc.
InstitutionAVUS - Avantis U.S. Equity ETF
Latest Disclosed Ownership84,862 shares
Latest Disclosed Value $ 1,958,614
AVUS - Avantis U.S. Equity ETF reports 75.72% increase in ownership of CPRX / Catalyst Pharmaceuticals, Inc.

On April 29, 2026 - AVUS - Avantis U.S. Equity ETF filed a NPORT-P form disclosing ownership of 84,862 shares of Catalyst Pharmaceuticals, Inc. (US:CPRX) valued at $1,958,615 USD as of February 28, 2026. The entity filed a previous NPORT-P on January 27, 2026 disclosing 48,293 shares of Catalyst Pharmaceuticals, Inc.. This represents a change in shares of 75.72% during the quarter. The current value of the position is $2,672,304 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-04-29 2026-02-28 NP Catalyst Pharmaceuticals EC US14888U1016 84,862 36,569 75.72 1,959 73.27 0.0174
2026-01-27 2025-11-30 NP Catalyst Pharmaceuticals EC US14888U1016 48,293 350 0.73 1,131 14.49 0.0110
2025-10-29 2025-08-31 NP Catalyst Pharmaceuticals EC US14888U1016 47,943 9,272 23.98 987 2.28 0.0104
2025-07-28 2025-05-31 NP Catalyst Pharmaceuticals EC US14888U1016 38,671 37,998 5,646.06 965 6,333.33 0.0117
2025-04-18 2025-02-28 NP Catalyst Pharmaceuticals EC US14888U1016 673 -33,406 -98.03 15 -97.83 0.0002
2024-10-28 2024-08-31 NP Catalyst Pharmaceuticals EC US14888U1016 34,079 -2,049 -5.67 690 18.15 0.0097
2024-07-23 2024-05-31 NP Catalyst Pharmaceuticals EC US14888U1016 36,128 0 0.00 584 0.86 0.0089
2024-04-19 2024-02-29 NP Catalyst Pharmaceuticals EC US14888U1016 36,128 -16,331 -31.13 579 -23.41 0.0093
2024-01-26 2023-11-30 NP Catalyst Pharmaceuticals EC US14888U1016 52,459 745 1.44 757 4.13 0.0148
2023-10-26 2023-08-31 NP Catalyst Pharmaceuticals EC US14888U1016 51,714 0 0.00 726 21.61 0.0156
2023-07-24 2023-05-31 NP Catalyst Pharmaceuticals EC US14888U1016 51,714 1,553 3.10 597 -21.96 0.0148
2023-04-26 2023-02-28 NP Catalyst Pharmaceuticals EC US14888U1016 50,161 6,836 15.78 765 5.37 0.0204
2023-01-19 2022-11-30 NP Catalyst Pharmaceuticals EC US14888U1016 43,325 21,118 95.10 727 142.00 0.0222
2022-10-26 2022-08-31 NP Catalyst Pharmaceuticals EC US14888U1016 22,207 9,361 72.87 301 226.09 0.0119
2022-07-28 2022-05-31 NP Catalyst Pharmaceuticals EC US14888U1016 12,846 7,353 133.86 92 119.05 0.0043
2022-04-25 2022-02-28 NP Catalyst Pharmaceuticals EC US14888U1016 5,493 0 0.00 43 10.53 0.0022
2022-01-24 2021-11-30 NP Catalyst Pharmaceuticals EC US14888U1016 5,493 0 0.00 38 26.67 0.0023
2021-10-27 2021-08-31 NP Catalyst Pharmaceuticals EC US14888U1016 5,493 0 0.00 30 0.00 0.0020
2021-07-26 2021-05-31 NP Catalyst Pharmaceuticals EC US14888U1016 5,493 0 0.00 30 42.86 0.0024
2021-04-22 2021-02-28 NP Catalyst Pharmaceuticals EC US14888U1016 5,493 0 0.00 21 5.00 0.0030
2021-01-25 2020-11-30 NP Catalyst Pharmaceuticals EC US14888U1016 5,493 2,097 61.75 20 81.82 0.0038
2020-10-23 2020-08-31 NP Catalyst Pharmaceuticals EC US14888U1016 3,396 455 15.47 11 -8.33 0.0026
2020-07-24 2020-05-31 NP Catalyst Pharmaceuticals EC US14888U1016 2,941 984 50.28 13 33.33 0.0039
2020-01-23 2019-11-30 NP Catalyst Pharmaceuticals EC US14888U1016 1,957 1,957 9 0.0056
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.